What will be the price of larotrectinib after it enters medical insurance in 2026?

Since its launch, Larotrectinib has become a bright spot in the field of precision therapy due to its innovation and therapeutic effect on specific cancer gene mutations. In 2026, larotrectinib has officially entered China's medical insurance, which means that more patients can obtain this drug within the scope of medical insurance reimbursement. However, because the price of larotrectinib’s original drug is still relatively high, the financial burden on patients is still considerable when using this drug.

According to the latest market data, the price of larotrectinib’s original drug is relatively high in China. The common specification is 100mg 56 capsule capsule preparation, which costs about 20,000 yuan. For oral solution preparations (specification: 50ml:1.0g2 bottles), the price is about 7,000 yuan. Although the price is higher, after larotrectinib has been included in medical insurance, patients can enjoy corresponding medical insurance reimbursement policies, thereby reducing treatment costs. For specific medical insurance reimbursement ratios and policies, patients need to consult the local hospital pharmacy and medical insurance department to understand the scope of reimbursement they can enjoy.

It is worth noting that larotrectinib, as a therapeutic drug, is mainly used to treat cancer patients who carryNTRK gene rearrangements. Therefore, the drug is only effective when used in patients who meet specific indications, and drug costs may vary accordingly. After being covered by medical insurance, the accessibility of larotrectinib has been improved, especially among some patient groups with relatively poor economic conditions. The medical insurance policy has alleviated a large financial burden for patients. Despite this, the cost of treatment with larotrectinib is still high, which is an important factor that patients need to consider when choosing a drug.

In general, after larotrectinib enters medical insurance, patients' financial burden will be alleviated to a certain extent, but it is still necessary to decide whether to use this drug based on specific medical insurance policies and personal economic conditions. With the further expansion of medical insurance coverage and the emergence of generic drugs, the price of larotrectinib may gradually decrease, thereby benefiting more patients.

Keyword tags: Larotrectinib, Larotrectinib, entry into medical insurance, drug prices, targeted drugs, NTRK gene rearrangement, medical insurance reimbursement, precision therapy, cancer treatment

Reference materials:https://en.wikipedia.org/wiki/Larotrectinib